Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. 1988

M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
Clinical Research Group BRWTI, Max Planck Society, Göttingen, Federal Republic of Germany.

In this paper we show that eight of 17 tumor cell lines of various tissue origin constitutively express tumor necrosis factor (TNF) mRNA. Five of these eight cell lines concomitantly contained lymphotoxin (LT) mRNA. Of the remaining nine cell lines that lacked detectable TNF or LT gene expression, five could be induced by phorbol ester and/or cytokines to accumulate the respective mRNAs. While TNF mRNA was found not only in neoplastic hematopoietic cells, but also in cell lines derived from carcinomas, LT gene expression seemed to be restricted to lymphoid tumor cells. Tumor cells that expressed LT mRNA also secreted LT protein and proved to be resistant to the cytostatic/cytotoxic effects of their own protein product as well as to exogenous recombinant TNF and recombinant LT. In contrast, most of the cell lines containing TNF mRNA did not release TNF protein into the supernatants, indicating that TNF gene expression may be controlled predominantly at a post-transcriptional level. Thus, the presence of TNF mRNA does not necessarily reflect a TNF-resistant phenotype. Our findings demonstrate that TNF and/or LT mRNA expression is a rather common phenomenon in long-term cultured tumor cell lines and reveal that ectopic TNF and/or LT production by tumor cells may be involved in certain paraneoplastic syndromes as well as in tumorigenesis.

UI MeSH Term Description Entries
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
February 1988, The Journal of clinical investigation,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
October 1986, The Journal of experimental medicine,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
August 1992, Nihon rinsho. Japanese journal of clinical medicine,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
February 1990, Blood,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
April 2010, IUBMB life,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
May 1987, Nucleic acids research,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
November 1990, The Journal of biological chemistry,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
March 1989, The American journal of pathology,
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
April 1998, Hepatology (Baltimore, Md.),
M Krönke, and G Hensel, and C Schlüter, and P Scheurich, and S Schütze, and K Pfizenmaier
January 1998, Molekuliarnaia biologiia,
Copied contents to your clipboard!